<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041938</url>
  </required_header>
  <id_info>
    <org_study_id>AAAC1093</org_study_id>
    <secondary_id>U01NS039143-01</secondary_id>
    <secondary_id>R01NS39154</secondary_id>
    <secondary_id>CRC</secondary_id>
    <nct_id>NCT00041938</nct_id>
  </id_info>
  <brief_title>Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial</brief_title>
  <acronym>WARCEF</acronym>
  <official_title>Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which of two treatments, Warfarin or aspirin, is
      better for preventing death and stroke in patients with poor heart function.

      We are now transitioning into the sub-analysis part of the WARCEF patient data.

      The study has recently completed data analysis for its Primary Aim. All randomized patients
      have completed their follow up. All study related procedure as per the protocol has been
      completed. We are now in the extension phase of the study to obtain more patient data to
      address further aims of the study. No new procedures are performed and data already in place
      at the sites will be collected (EKG and echocardiograms).

      The aims for this study extension are:

        -  To assess progression of cardiac dysfunction over time among heart failure patients

        -  To correlate prognosis with cardiac dysfunction
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Warfarin has proven effective in patients with ischemic heart disease, especially in the
      reduction of stroke, death and re-infarction following myocardial infarction, and in the
      reduction of stroke in atrial fibrillation. Warfarin is the most promising unstudied
      intervention in patients with cardiac failure. This randomized, double-blind, multi-center
      study will define optimal antithrombotic therapy for patients with cardiac (heart) failure
      and patients with low ejection fraction (EF). EF is the proportion of left ventricular volume
      emptied during systole. It reliably measures left ventricular systolic function.

      With the rapidly increasing numbers of elderly patients with heart failure, this study has
      important public health implications. The study will determine which of two commonly used
      treatments Warfarin, an anticoagulant, or aspirin, a drug which affects platelet function is
      better for preventing death and stroke in patients with low ejection fraction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Rate Per 100 Patient Years for Composite Endpoint of Ischemic Stroke, Intracerebral Hemorrhage, or Death</measure>
    <time_frame>From date of randomization until the date of the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to 6 years</time_frame>
    <description>The time, in years, from randomization to the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years. Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Rate Per 100 Patient-years for Composite Endpoint of Hospitalization for Heart Failure, Myocardial Infarction, Ischemic Stroke, Intracerebral Hemorrhage, or Death.</measure>
    <time_frame>From randomization to the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years.</time_frame>
    <description>The time, in years, from date of randomization to the date of the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to 6 years.
Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Event Rate Per 100 Patient-years for Ischemic Stroke</measure>
    <time_frame>From date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years</time_frame>
    <description>Time, in years, from date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
  </other_outcome>
  <other_outcome>
    <measure>Event Rate Per 100 Patient-years for Intracerebral Hemorrhage</measure>
    <time_frame>From date of randomization to date of intracerebral hemorrhage component of primary composite outcome, up to 6 years</time_frame>
    <description>Time, in years, from date of randomization to date of intracerebral hemorrhage component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
  </other_outcome>
  <other_outcome>
    <measure>Event Rate Per 100 Patient-years for Death</measure>
    <time_frame>From date of randomization to date of death component of primary composite outcome, up to 6 years</time_frame>
    <description>Time, in years, from date of randomization to date of death component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
  </other_outcome>
  <other_outcome>
    <measure>Event Rate Per 100 Patient Years of Myocardial Infarction Component of Secondary Composite Outcome</measure>
    <time_frame>From date of randomization to date of myocardial infarction component of secondary composite outcome, up to 6 years</time_frame>
    <description>Time, in years, from date of randomization to date of myocardial infarction, up to 6 years. Includes only myocardial infarctions that occurred during follow-up, before any heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with myocardial infarction)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
  </other_outcome>
  <other_outcome>
    <measure>Event Rate Per 100 Patient Years of Heart Failure Hospitalization Component of Secondary Composite Outcome.</measure>
    <time_frame>From date of randomization to date of heart failure hospitalization component of secondary composite outcome, up to 6 years</time_frame>
    <description>Time, in years, from date of randomization to date of heart failure hospitalization, up to 6 years. Includes hospitalizations for heart failure during follow-up that were not preceded by myocardial infarction. Event rate per 100 patient years = 100*(number of subjects with heart failure hospitalization)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
  </other_outcome>
  <other_outcome>
    <measure>Event Rate Per 100 Patient Years of Ischemic Stroke Component of Secondary Composite Outcome</measure>
    <time_frame>From date of randomization to date of ischemic stroke component of secondary composite outcome, up to 6 years</time_frame>
    <description>Ischemic stroke component of secondary composite endpoint. Includes only ischemic strokes that were not preceded by a myocardial infarction or heart failure hospitalization. The number of ischemic strokes that are components of the secondary outcome does not therefore match the number of ischemic strokes that are components of the primary outcome. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25.</description>
  </other_outcome>
  <other_outcome>
    <measure>Event Rate Per 100 Patient Years of Intracerebral Hemorrhage Component of Secondary Composite Outcome</measure>
    <time_frame>From date of randomization to date of intracerebral hemorrhage component of secondary composite outcome, up to 6 years</time_frame>
    <description>Time, in years, from date of randomization to date of intracerebral hemorrhage component of secondary composite outcome. Includes only intracerebral hemorrhages not preceded by myocardial infarction or heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
  </other_outcome>
  <other_outcome>
    <measure>Event Rate Per 100 Patient Years of Death Component of Secondary Composite Outcome</measure>
    <time_frame>From date of randomization to date of death component of secondary composite outcome, up to 6 years</time_frame>
    <description>Time, in years, from randomization to death component of secondary composite outcome. This measure counts only deaths that were not preceded by heart failure hospitalization, myocardial infarction, ischemic stroke, or intracerebral hemorrhage. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate Per 100 Patient Years of Major Hemorrhage</measure>
    <time_frame>From date of randomization until end of scheduled follow-up, up to 6 years</time_frame>
    <description>Rate/100 patient-years of major hemorrhage. Includes all major hemorrhages in any patient. Major hemorrhage was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the hemoglobin level of more than 2 g per deciliter in 48 hours; or bleeding requiring transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. Event rate per 100 patient years = 100*(number of major hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate Per 100 Patient-years of Minor Hemorrhage.</measure>
    <time_frame>From date of randomization until the end of scheduled follow-up, up to 6 years</time_frame>
    <description>Rate per 100 patient years of minor hemorrhage. Includes all minor hemorrhages. Minor hemorrhage was defined as any non-major hemorrhage. Event rate per 100 patient years = 100*(number of minor hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2305</enrollment>
  <condition>Heart Disease</condition>
  <condition>Stroke</condition>
  <condition>Ischemic Heart Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin: 325 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Warfarin: International Normalized Ratio (INR) 2.5-3.0; target INR 2.75</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>325 mg per day</description>
    <arm_group_label>aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>INR 2.5-3.0; target INR 2.75</description>
    <arm_group_label>warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Cardiac EF &lt;=35% by radionuclide ventriculography, left ventriculography or quantitive
             echocardiographic measurement or an echocardiographic Wall Motion Index of &lt;=1.2,
             within three months of enrollment. The patient's clinical cardiac state at enrollment
             should be similar to their state at the time of the qualifying echocardiogram. The
             qualifying left ventricular function measurement must be obtained at least three
             months after an MI, coronary bypass grafting, PTCA, and at least one month after
             pacemaker insertion. Patients scheduled for mitral valve repair should have qualifying
             echo after surgery.

          -  Modified Rankin score &lt;=4.

          -  Patient must be taking ACE inhibitors. If intolerant of ACE inhibitor, patient must be
             on angiotensin II receptor blockers or hydralazine and nitrates.

          -  Patient is able to follow an outpatient protocol (requiring monthly blood tests and
             clinic visits every four months for the duration of the study) and is available by
             telephone.

          -  Patient understands the purpose and requirements of the study, can make him/herself
             understood, and has provided informed consent.

          -  Patients with recent stroke or TIA within twelve (12) months will be eligible to be
             included in the recent stroke (RS) subgroup.

          -  Chronic CHF patients (NYHA I * IV) admitted to the hospital can be randomized prior to
             discharge if the patient is stable, taking oral medications for 24 hours and
             ambulatory at the time of discharge. Stable New York Heart Association Class IV
             patients will be eligible for randomization.

        Exclusion Criteria

          -  The presence of any of the following unequivocal cardiac sources of embolism: chronic
             or paroxysmal AF, mechanical valve, endocarditis, intracardiac mobile or pedunculated
             thrombus, and valvular vegetation.

          -  Cyanotic congenital heart disease, Eisenmenger's syndrome.

          -  Decompensated heart failure.

          -  Cardiac surgery, angioplasty, or MI within the past 3 months prior to randomization.

          -  A contraindication to the use of either warfarin or aspirin, e.g. active peptic ulcer
             disease, active bleeding diathesis, platelets &lt;100,000*, hematocrit &lt;30, INR &gt;1.3 (if
             not on warfarin), clotting factor abnormality that increases the risk of bleeding,
             alcohol or substance abuse, severe gait instability, cerebral hemorrhage, systemic
             hemorrhage within the past year, severe liver impairment (AST &gt;3x normal*, cirrhosis),
             any condition requiring regular use of non-steroidal anti-inflammatory agents, allergy
             to aspirin or warfarin, uncontrolled severe hypertension (systolic pressure &gt;180 mm Hg
             or diastolic pressure &gt; 110 mm Hg), positive stool guaiac not attributable to
             hemorrhoids, creatinine &gt;3.0*. *on most recent test done within 30 days prior to
             randomization

          -  Patient needs continuing therapy with intravenous heparin or low molecular weight
             heparin or a specific antiplatelet agent.

          -  Dementia or psychiatric or physical problem that prevents the patient from following
             an outpatient program reliably.

          -  Comorbid conditions that may limit survival to less than five years.

          -  Pregnancy, or female of childbearing potential who is not sterilized or is not using a
             medically accepted form of contraception* (see procedure manual). *A pregnancy test is
             required for all women of childbearing age.

          -  Enrollment in another study that would conflict with WARCEF.

          -  Hospitalization for new diagnosis of onset CHF within the past one month or carotid
             endarterectomy or pacemaker insertion within the past one month prior to randomization
             .

          -  Person under 18 years of age.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shunichi Homma, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Cardiologist, Associate Chief, Division of Cardiology, and Director, Echocardiography Laboratories Professor of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seamus Thompson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Statistical PI: Clinical Professor of Biostatistics and Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Arizona Veterans Affairs Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Clara Medical Center</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Los Angeles Veterans Affairs Medical Center</name>
      <address>
        <city>West Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Veterans Affairs Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Transplant Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melbourne Internal Medicine Associates</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Memorial Hospital/U. of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Consultants of South Florida</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morehouse School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Heart Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Heart, Lung and Vascular Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisville Veterans Affairs Medical Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Regional Research, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health Sciences Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Partners</name>
      <address>
        <city>Muskegon</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reno Veterans Affairs Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Hospital</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ - New Brunswick</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Medicine and Dentistry of New Jersey</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buffalo General Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaleida Health Millard Fillmore Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Five Towns Neuroscience Research</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University, New York Presbyterian Hospital PH 3-342</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northport Veterans Affairs Medical Center</name>
      <address>
        <city>Northport</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma City Veterans Affairs Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-State Medical Group Cardiology</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sewickley Valley Medical Group, Cardiology</name>
      <address>
        <city>Leetsdale</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Presbyterian Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Health Care System</name>
      <address>
        <city>Fort Meade</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center MCHE - MDC Cardiology Service</name>
      <address>
        <city>Ft. Sam Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael E. DeBakey Veterans Affairs Medical Center-MEDVAMC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salem VAMC</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntington Veterans Affairs Medical Center</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William S. Middleton Memorial Veterans Hospital</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Neurologic Research</name>
      <address>
        <city>Lethbridge</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QE II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Etobicoke Cardiac Research Centre</name>
      <address>
        <city>Rexdale</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2002</study_first_submitted>
  <study_first_submitted_qc>July 19, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2002</study_first_posted>
  <results_first_submitted>January 3, 2013</results_first_submitted>
  <results_first_submitted_qc>April 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 14, 2013</results_first_posted>
  <last_update_submitted>August 29, 2014</last_update_submitted>
  <last_update_submitted_qc>August 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Shunichi Homma</investigator_full_name>
    <investigator_title>Margaret Milliken Hatch Professor of Medicine at the New York-Presbyterian Hospital at the Columbia University Medical Center (In Biomedical Engineering)</investigator_title>
  </responsible_party>
  <keyword>heart disease</keyword>
  <keyword>stroke</keyword>
  <keyword>ischemic heart disease</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>low ejection fraction</keyword>
  <keyword>cardiac failure</keyword>
  <keyword>aspirin</keyword>
  <keyword>Warfarin</keyword>
  <keyword>anticoagulant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited 2305 patients at 176 sites in 11 countries, between 10/1/2002 and 1/31/2010.</recruitment_details>
      <pre_assignment_details>Intent-to-treat trial - all randomized patients followed and analyzed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aspirin</title>
          <description>Aspirin : 325 mg per day</description>
        </group>
        <group group_id="P2">
          <title>Warfarin</title>
          <description>Warfarin : International Normalized Ratio (INR) 2.5-3.0; target INR 2.75</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1163"/>
                <participants group_id="P2" count="1142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="761"/>
                <participants group_id="P2" count="745"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Primary Endpoint</title>
              <participants_list>
                <participants group_id="P1" count="320"/>
                <participants group_id="P2" count="302"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Only Vital Status Known</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1125"/>
                <participants group_id="P2" count="1111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aspirin</title>
          <description>Aspirin : 325 mg per day</description>
        </group>
        <group group_id="B2">
          <title>Warfarin</title>
          <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1163"/>
            <count group_id="B2" value="1142"/>
            <count group_id="B3" value="2305"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="732"/>
                    <measurement group_id="B2" value="706"/>
                    <measurement group_id="B3" value="1438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="431"/>
                    <measurement group_id="B2" value="436"/>
                    <measurement group_id="B3" value="867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="11.1"/>
                    <measurement group_id="B2" value="61" spread="11.6"/>
                    <measurement group_id="B3" value="61" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="936"/>
                    <measurement group_id="B2" value="904"/>
                    <measurement group_id="B3" value="1840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="546"/>
                    <measurement group_id="B2" value="573"/>
                    <measurement group_id="B3" value="1119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="567"/>
                    <measurement group_id="B2" value="527"/>
                    <measurement group_id="B3" value="1094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Event Rate Per 100 Patient Years for Composite Endpoint of Ischemic Stroke, Intracerebral Hemorrhage, or Death</title>
        <description>The time, in years, from randomization to the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years. Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
        <time_frame>From date of randomization until the date of the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to 6 years</time_frame>
        <population>Intent-to-treat analysis: all enrolled patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Aspirin : 325 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate Per 100 Patient Years for Composite Endpoint of Ischemic Stroke, Intracerebral Hemorrhage, or Death</title>
          <description>The time, in years, from randomization to the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years. Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
          <population>Intent-to-treat analysis: all enrolled patients were analyzed.</population>
          <units>events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
                <count group_id="O2" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.93"/>
                    <measurement group_id="O2" value="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary null hypothesis: time to first event in the composite primary endpoint does not differ significantly between warfarin and aspirin. The original target sample size was 2860, providing 89% power for a log-rank test with two-sided alpha .05, assuming a hazard rate reduction of 17.82% in either group compared with the other, after adjustment for use of beta-blockers and allowance for discontinuation of therapy, dropout, and crossover. The final sample of 2305 patients yielded 69% power.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <p_value_desc>The primary null hypotheses was tested at two-tailed alpha=0.05. A Haybittle-Peto interim monitoring procedure was performed with stopping boundaries for the interim analyses corresponding to a nominal two-tailed P value of 0.001.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Cox models stratified by site, New York Heart Association class (I vs. II-IV), and status w/ respect to recent stroke or Transient Ischemic Attack.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
            <estimate_desc>Hazard ratio is for comparison of warfarin vs. aspirin. Warfarin represents the numerator and aspirin represents the denominator of the hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate Per 100 Patient-years for Composite Endpoint of Hospitalization for Heart Failure, Myocardial Infarction, Ischemic Stroke, Intracerebral Hemorrhage, or Death.</title>
        <description>The time, in years, from date of randomization to the date of the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to 6 years.
Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
        <time_frame>From randomization to the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years.</time_frame>
        <population>Intent-to-treat analysis: all enrolled patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Aspirin : 325 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate Per 100 Patient-years for Composite Endpoint of Hospitalization for Heart Failure, Myocardial Infarction, Ischemic Stroke, Intracerebral Hemorrhage, or Death.</title>
          <description>The time, in years, from date of randomization to the date of the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to 6 years.
Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
          <population>Intent-to-treat analysis: all enrolled patients were analyzed.</population>
          <units>events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
                <count group_id="O2" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.15"/>
                    <measurement group_id="O2" value="12.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Secondary null hypothesis: time to first event in the composite secondary endpoint does not differ significantly between warfarin and aspirin. This was tested at prespecified alpha = 0.05 level, two-tailed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <p_value_desc>Secondary null hypothesis was tested at two-tailed alpha = 0.05.</p_value_desc>
            <method>Regression, Cox</method>
            <method_desc>Cox models stratified by site, New York Heart Association class (I vs. II-IV), and status w/ respect to recent stroke or Transient Ischemic Attack.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Hazard ratio is for comparison of warfarin vs. aspirin. Warfarin represents the numerator and aspirin represents the denominator of the hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Event Rate Per 100 Patient-years for Ischemic Stroke</title>
        <description>Time, in years, from date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
        <time_frame>From date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Aspirin : 325 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate Per 100 Patient-years for Ischemic Stroke</title>
          <description>Time, in years, from date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
          <population>Intent-to-treat</population>
          <units>rate per 100 patient years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
                <count group_id="O2" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36"/>
                    <measurement group_id="O2" value="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference between warfarin and aspirin in time to ischemic stroke, adjusting for competing risks of death and intracerebral hemorrhage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cause-specific Cox model, stratified by site, NYHA class (I vs. II, III, or IV), and prior stroke or TIA status.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
            <estimate_desc>Hazard ratio is for comparison of warfarin vs. aspirin. Warfarin represents the numerator and aspirin represents the denominator of the hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Event Rate Per 100 Patient-years for Intracerebral Hemorrhage</title>
        <description>Time, in years, from date of randomization to date of intracerebral hemorrhage component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
        <time_frame>From date of randomization to date of intracerebral hemorrhage component of primary composite outcome, up to 6 years</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Aspirin : 325 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate Per 100 Patient-years for Intracerebral Hemorrhage</title>
          <description>Time, in years, from date of randomization to date of intracerebral hemorrhage component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
          <population>Intent-to-treat</population>
          <units>rate per 100 patient years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
                <count group_id="O2" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05"/>
                    <measurement group_id="O2" value="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference between warfarin and aspirin in time to intracerebral hemorrhage, adjusting for competing risks of death and ischemic stroke.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cause-specific Cox model, stratified by site, NYHA class (I vs. II, III, or IV), and prior stroke or TIA status.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>11.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Event Rate Per 100 Patient-years for Death</title>
        <description>Time, in years, from date of randomization to date of death component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
        <time_frame>From date of randomization to date of death component of primary composite outcome, up to 6 years</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Aspirin : 325 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate Per 100 Patient-years for Death</title>
          <description>Time, in years, from date of randomization to date of death component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
          <population>Intent-to-treat</population>
          <units>events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
                <count group_id="O2" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.52"/>
                    <measurement group_id="O2" value="6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.91</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cause-specific Cox model, stratified by site, NYHA class (I vs. II, III, or IV), and prior stroke or TIA status.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>Hazard ratio is for comparison of warfarin vs. aspirin. Warfarin represents the numerator and aspirin represents the denominator of the hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Event Rate Per 100 Patient Years of Myocardial Infarction Component of Secondary Composite Outcome</title>
        <description>Time, in years, from date of randomization to date of myocardial infarction, up to 6 years. Includes only myocardial infarctions that occurred during follow-up, before any heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with myocardial infarction)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
        <time_frame>From date of randomization to date of myocardial infarction component of secondary composite outcome, up to 6 years</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Aspirin : 325 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate Per 100 Patient Years of Myocardial Infarction Component of Secondary Composite Outcome</title>
          <description>Time, in years, from date of randomization to date of myocardial infarction, up to 6 years. Includes only myocardial infarctions that occurred during follow-up, before any heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with myocardial infarction)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
          <population>Intent-to-treat</population>
          <units>events per 100 patient years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
                <count group_id="O2" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87"/>
                    <measurement group_id="O2" value="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference between warfarin and aspirin in time to myocardial infarction, adjusting for competing risks of heart failure hospitalization, ischemic stroke, intracerebral hemorrhage, and death.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cause-specific Cox model, stratified by site, NYHA class (I vs. II, III, or IV), and prior stroke or TIA status.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
            <estimate_desc>Hazard ratio is for comparison of warfarin vs. aspirin. Warfarin represents the numerator and aspirin represents the denominator of the hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Event Rate Per 100 Patient Years of Heart Failure Hospitalization Component of Secondary Composite Outcome.</title>
        <description>Time, in years, from date of randomization to date of heart failure hospitalization, up to 6 years. Includes hospitalizations for heart failure during follow-up that were not preceded by myocardial infarction. Event rate per 100 patient years = 100*(number of subjects with heart failure hospitalization)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
        <time_frame>From date of randomization to date of heart failure hospitalization component of secondary composite outcome, up to 6 years</time_frame>
        <population>Intent-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Aspirin : 325 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate Per 100 Patient Years of Heart Failure Hospitalization Component of Secondary Composite Outcome.</title>
          <description>Time, in years, from date of randomization to date of heart failure hospitalization, up to 6 years. Includes hospitalizations for heart failure during follow-up that were not preceded by myocardial infarction. Event rate per 100 patient years = 100*(number of subjects with heart failure hospitalization)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
          <population>Intent-to-treat.</population>
          <units>events per 100 patient years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
                <count group_id="O2" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.67"/>
                    <measurement group_id="O2" value="6.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference between warfarin and aspirin in time to heart failure hospitalization, adjusting for competing risks of myocardial infarction, ischemic stroke, intracerebral hemorrhage, and death.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.053</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cause-specific Cox model, stratified by site, NYHA class (I vs. II, III, or IV), and prior stroke or TIA status.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.998</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Event Rate Per 100 Patient Years of Ischemic Stroke Component of Secondary Composite Outcome</title>
        <description>Ischemic stroke component of secondary composite endpoint. Includes only ischemic strokes that were not preceded by a myocardial infarction or heart failure hospitalization. The number of ischemic strokes that are components of the secondary outcome does not therefore match the number of ischemic strokes that are components of the primary outcome. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25.</description>
        <time_frame>From date of randomization to date of ischemic stroke component of secondary composite outcome, up to 6 years</time_frame>
        <population>Intent-to-treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Aspirin : 325 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate Per 100 Patient Years of Ischemic Stroke Component of Secondary Composite Outcome</title>
          <description>Ischemic stroke component of secondary composite endpoint. Includes only ischemic strokes that were not preceded by a myocardial infarction or heart failure hospitalization. The number of ischemic strokes that are components of the secondary outcome does not therefore match the number of ischemic strokes that are components of the primary outcome. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25.</description>
          <population>Intent-to-treat.</population>
          <units>events per 100 patient years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
                <count group_id="O2" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14"/>
                    <measurement group_id="O2" value="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference between warfarin and aspirin in time to ischemic stroke, adjusting for competing risks of myocardial infarction, heart failure hospitalization, death and intracerebral hemorrhage.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cause-specific Cox model, stratified by site, NYHA class (I vs. II, III, or IV), and prior stroke or TIA status.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Event Rate Per 100 Patient Years of Intracerebral Hemorrhage Component of Secondary Composite Outcome</title>
        <description>Time, in years, from date of randomization to date of intracerebral hemorrhage component of secondary composite outcome. Includes only intracerebral hemorrhages not preceded by myocardial infarction or heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
        <time_frame>From date of randomization to date of intracerebral hemorrhage component of secondary composite outcome, up to 6 years</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Aspirin : 325 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate Per 100 Patient Years of Intracerebral Hemorrhage Component of Secondary Composite Outcome</title>
          <description>Time, in years, from date of randomization to date of intracerebral hemorrhage component of secondary composite outcome. Includes only intracerebral hemorrhages not preceded by myocardial infarction or heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
          <population>Intent-to-treat</population>
          <units>events per 100 patient years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
                <count group_id="O2" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06"/>
                    <measurement group_id="O2" value="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference between warfarin and aspirin in time to intracerebral hemorrhage, adjusting for competing risks of myocardial infarction, heart failure hospitalization, ischemic stroke, and death.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cause-specific Cox model, stratified by site, NYHA class (I vs. II, III, or IV), and prior stroke or TIA status.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>9.88</ci_upper_limit>
            <estimate_desc>Hazard ratio is for comparison of warfarin vs. aspirin. Warfarin represents the numerator and aspirin represents the denominator of the hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Event Rate Per 100 Patient Years of Death Component of Secondary Composite Outcome</title>
        <description>Time, in years, from randomization to death component of secondary composite outcome. This measure counts only deaths that were not preceded by heart failure hospitalization, myocardial infarction, ischemic stroke, or intracerebral hemorrhage. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
        <time_frame>From date of randomization to date of death component of secondary composite outcome, up to 6 years</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Aspirin : 325 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate Per 100 Patient Years of Death Component of Secondary Composite Outcome</title>
          <description>Time, in years, from randomization to death component of secondary composite outcome. This measure counts only deaths that were not preceded by heart failure hospitalization, myocardial infarction, ischemic stroke, or intracerebral hemorrhage. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
          <population>Intent-to-treat</population>
          <units>events per 100 patient years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
                <count group_id="O2" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41"/>
                    <measurement group_id="O2" value="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cause-specific Cox model, stratified by site, NYHA class (I vs. II, III, or IV), and prior stroke or TIA status.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rate Per 100 Patient Years of Major Hemorrhage</title>
        <description>Rate/100 patient-years of major hemorrhage. Includes all major hemorrhages in any patient. Major hemorrhage was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the hemoglobin level of more than 2 g per deciliter in 48 hours; or bleeding requiring transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. Event rate per 100 patient years = 100*(number of major hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
        <time_frame>From date of randomization until end of scheduled follow-up, up to 6 years</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Aspirin : 325 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
          </group>
        </group_list>
        <measure>
          <title>Rate Per 100 Patient Years of Major Hemorrhage</title>
          <description>Rate/100 patient-years of major hemorrhage. Includes all major hemorrhages in any patient. Major hemorrhage was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the hemoglobin level of more than 2 g per deciliter in 48 hours; or bleeding requiring transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. Event rate per 100 patient years = 100*(number of major hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25.</description>
          <population>Intent-to-treat</population>
          <units>events per 100 patient years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
                <count group_id="O2" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87"/>
                    <measurement group_id="O2" value="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Poisson</method>
            <param_type>Rate ratio</param_type>
            <param_value>2.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.36</ci_lower_limit>
            <ci_upper_limit>3.12</ci_upper_limit>
            <estimate_desc>The warfarin arm represents the numerator and the aspirin arm represents the denominator of the rate ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Rate Per 100 Patient-years of Minor Hemorrhage.</title>
        <description>Rate per 100 patient years of minor hemorrhage. Includes all minor hemorrhages. Minor hemorrhage was defined as any non-major hemorrhage. Event rate per 100 patient years = 100*(number of minor hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25.</description>
        <time_frame>From date of randomization until the end of scheduled follow-up, up to 6 years</time_frame>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aspirin</title>
            <description>Aspirin : 325 mg per day</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
          </group>
        </group_list>
        <measure>
          <title>Rate Per 100 Patient-years of Minor Hemorrhage.</title>
          <description>Rate per 100 patient years of minor hemorrhage. Includes all minor hemorrhages. Minor hemorrhage was defined as any non-major hemorrhage. Event rate per 100 patient years = 100*(number of minor hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25.</description>
          <population>Intent-to-treat</population>
          <units>events per 100 patient-years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1163"/>
                <count group_id="O2" value="1142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.34"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Poisson</method>
            <param_type>Rate ratio</param_type>
            <param_value>1.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.34</ci_lower_limit>
            <ci_upper_limit>1.81</ci_upper_limit>
            <estimate_desc>Warfarin group represents the numerator and aspirin group represents denominator of rate ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aspirin</title>
          <description>Aspirin : 325 mg per day</description>
        </group>
        <group group_id="E2">
          <title>Warfarin</title>
          <description>Warfarin : INR 2.5-3.0; target INR 2.75</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="617" subjects_at_risk="1163"/>
                <counts group_id="E2" subjects_affected="632" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood dyscrasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1163"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>BLOOD/BONE MARROW: Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia/Anemia/Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>LYMPHATICS: Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1163"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation/Atrial flutter/Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="67" subjects_affected="56" subjects_at_risk="1163"/>
                <counts group_id="E2" events="45" subjects_affected="35" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1163"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>CARDIAC ARRHYTHMIA: Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1163"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1163"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="24" subjects_at_risk="1163"/>
                <counts group_id="E2" events="46" subjects_affected="39" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Acute cardiac failure/CHF/Pulmonary edema</sub_title>
                <counts group_id="E1" events="432" subjects_affected="209" subjects_at_risk="1163"/>
                <counts group_id="E2" events="506" subjects_affected="243" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>AICD firing/discharge</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="1163"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Angina/Chest pain</sub_title>
                <counts group_id="E1" events="105" subjects_affected="70" subjects_at_risk="1163"/>
                <counts group_id="E2" events="148" subjects_affected="88" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>CARDIAC GENERAL: Other</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="1163"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1163"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Myocardial infarction/Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="60" subjects_affected="48" subjects_at_risk="1163"/>
                <counts group_id="E2" events="59" subjects_affected="50" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1163"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus and its complications</sub_title>
                <counts group_id="E1" events="35" subjects_affected="26" subjects_at_risk="1163"/>
                <counts group_id="E2" events="35" subjects_affected="22" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>ENDOCRINE: Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>OCULAR/VISUAL: Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="1163"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disturbance/Diarrhea/Jaundice/Nausea/Stomach pain/Etc.</sub_title>
                <counts group_id="E1" events="70" subjects_affected="54" subjects_at_risk="1163"/>
                <counts group_id="E2" events="82" subjects_affected="66" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL: Other</sub_title>
                <counts group_id="E1" events="31" subjects_affected="25" subjects_at_risk="1163"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY/IMMUNOLOGY: Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Laryngeal edema/Allergic reaction/Anaphylaxis/Angioedema/Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1163"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>CONSTITUTIONAL SYMPTOMS: Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>OTHER: Other</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="1163"/>
                <counts group_id="E2" events="33" subjects_affected="32" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Suicide attempt/Psychiatric disorder</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="1163"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>PAIN: Other</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="1163"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1163"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>HEPATOBILIARY/PANCREAS: Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1163"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection/Sepsis/Fever</sub_title>
                <counts group_id="E1" events="79" subjects_affected="66" subjects_at_risk="1163"/>
                <counts group_id="E2" events="97" subjects_affected="79" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic disturbance/Gout</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="1163"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY: Other</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="1163"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL/SOFT TISSUE: Other</sub_title>
                <counts group_id="E1" events="43" subjects_affected="39" subjects_at_risk="1163"/>
                <counts group_id="E2" events="32" subjects_affected="29" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Visceral necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1163"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>MALIGNANCY: Other</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="1163"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsions/Seizures</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1163"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>NEUROLOGY: Other</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="1163"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Stroke or TIA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="1163"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Syncope/Pre-syncope</sub_title>
                <counts group_id="E1" events="48" subjects_affected="41" subjects_at_risk="1163"/>
                <counts group_id="E2" events="83" subjects_affected="68" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure/Proteinuria</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="1163"/>
                <counts group_id="E2" events="36" subjects_affected="33" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>RENAL/GENITOURINARY: Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1163"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>SEXUAL/REPRODUCTIVE FUNCTION: Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1163"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1163"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Pulmonary disease/Pneumonia/Bronchitis/Asthma/Breathing difficulties</sub_title>
                <counts group_id="E1" events="133" subjects_affected="87" subjects_at_risk="1163"/>
                <counts group_id="E2" events="100" subjects_affected="79" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>PULMONARY/UPPER RESPIRATORY: Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1163"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATOLOGY/SKIN: Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Grade 4 dermatologic manifestations</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1163"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>&quot;Cardiac device implantation (pacemaker, defibrillator, etc.)&quot;</sub_title>
                <counts group_id="E1" events="133" subjects_affected="123" subjects_at_risk="1163"/>
                <counts group_id="E2" events="118" subjects_affected="109" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>&quot;Cardiac procedure (stent, catheterization, EP study, ablation, etc.)&quot;</sub_title>
                <counts group_id="E1" events="76" subjects_affected="62" subjects_at_risk="1163"/>
                <counts group_id="E2" events="82" subjects_affected="66" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Cardiac surgery</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="1163"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>Non-cardiac surgery/Diagnostic surgery</sub_title>
                <counts group_id="E1" events="102" subjects_affected="75" subjects_at_risk="1163"/>
                <counts group_id="E2" events="67" subjects_affected="57" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>SURGERY/INTRA-OPERATIVE INJURY: Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1163"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1163"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1142"/>
              </event>
              <event>
                <sub_title>VASCULAR: Other</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="1163"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="749" subjects_at_risk="1163"/>
                <counts group_id="E2" subjects_affected="799" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>All non-serious adverse events</sub_title>
                <counts group_id="E1" events="4483" subjects_affected="749" subjects_at_risk="1163"/>
                <counts group_id="E2" events="4895" subjects_affected="799" subjects_at_risk="1142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. J.L.P. (Seamus) Thompson</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-342-1252</phone>
      <email>jlt12@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

